



# Altuviio in India

*The CDSCO named-patient coordination pathway — indicative 2026*

HEMATOLOGY · HEMOPHILIA A (ONCE-WEEKLY FACTOR VIII)

## The clinical situation

Altuviio (efanesoctocog alfa) is a first-in-class once-weekly extended-half-life factor VIII, FDA-approved for routine prophylaxis, on-demand treatment, and perioperative management in adults and children with Hemophilia A. Developed by Sanofi and Sobi, it is built as an Fc-VWF-XTEN fusion that extends circulating half-life well beyond conventional and earlier extended-half-life factor VIII products. Delivered as a once-weekly IV infusion — contrasting with standard FVIII (every 2–3 days) and earlier EHL products (every 3–5 days). Eligibility is clinical, based on bleed phenotype, adherence to current prophylaxis, inhibitor status, and response to prior FVIII therapies.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist documents bleed history, current prophylaxis regimen, response, and the rationale for once-weekly Altuviio.
- 2 CDSCO personal-import / named-patient application.** Physician or importing pharmacy files dossier: rationale, patient reference, weight-based once-weekly dosing plan.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 4 Cold-chain shipment.** Temperature-controlled transport with documented chain of custody.
- 5 Arrival, infusion & re-supply.** Day-care or home infusion per physician protocol; Reserve Meds supports re-supply cadence aligned to once-weekly dosing.

### Indicative economics

**Reference US cash-pay range:** Weight- and dose-dependent; extended dosing interval partially offsets per-dose cost versus standard FVIII. Reserve Meds issues a transparent delivered quote at intake.

### Indicative first-dose timing

**10–21 days** from a complete CDSCO application to first shipment; re-supply faster once pathway established. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and CDSCO review, keyed to the once-weekly FVIII rationale. **Logistics.** Cold-chain shipment with continuous temperature monitoring and importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team; ongoing re-supply coordination. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Altuviio × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/altuviio-india.html](https://reservemed.com/access-guides/altuviio-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team